Blood-based oxidation markers in medicated and unmedicated schizophrenia patients: A meta-analysis

Goh, Xue Xin; Tang, Pek Yee; Tee, Shiau Foon

doi:10.1016/j.ajp.2021.102932

Cited by 12 publications

(10 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GSH deficiency also contributes to myelination abnormalities, which may have a significant impact on the deterioration of cognitive function in schizophrenia [ 3 ]. A negative correlation was also found between the activity of GPx, an enzyme belonging to the glutathione system, and the severity of cerebral atrophy in patients with chronic schizophrenia [ 66 ]. Impaired antioxidant activity and its influence on structural and functional changes in the CNS may explain the association between lower GSH levels and greater severity of negative symptoms.…”

Section: Discussionmentioning

confidence: 99%

Oxidative Stress Biomarkers among Schizophrenia Inpatients

et al. 2023

View full text Add to dashboard Cite

Background. Finding the associations between schizophrenia symptoms and the biomarkers of inflammation, oxidative stress and the kynurenine pathway may lead to the individualization of treatment and increase its effectiveness. Methods. The study group included 82 schizophrenia inpatients. The Positive and Negative Symptoms Scale (PANSS), the Brief Assessment of Cognition in Schizophrenia (BACS) and the Calgary Depression in Schizophrenia Scale were used for symptom evaluation. Biochemical analyses included oxidative stress parameters and brain-derived neurotrophic factor (BDNF). Results. Linear models revealed the following: (1) malondiadehyde (MDA), N-formylkynurenine (N-formKYN), advanced oxidation protein products (AOPP), advanced glycation end-products of proteins (AGE) and total oxidative status (TOS) levels are related to the PANSS-total score; (2) MDA, reduced glutathione (GSH) and BDNF levels are related to the PANSS-negative score; (3) TOS and kynurenine (KYN) levels are related to the PANSS-positive score; (4) levels of total antioxidant status (TAS) and AOPP along with the CDSS score are related to the BACS-total score; (5) TAS and N-formKYN levels are related to the BACS-working memory score. Conclusions. Oxidative stress biomarkers may be associated with the severity of schizophrenia symptoms in positive, negative and cognitive dimensions. The identification of biochemical markers associated with the specific symptom clusters may increase the understanding of biochemical profiles in schizophrenia patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Oxidative Stress Biomarkers among Schizophrenia Inpatients

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Indeed, MDA is a product of lipid peroxidation. Multiple studies have demonstrated that patients with SZ have higher blood concentration of MDA [ 39 , 69 , 70 , 76 ] and NO, including two meta-analyses [ 82 , 83 ]. One of these studies revealed the good diagnostic performance for serum MDA levels in SZ patients [ 69 ].…”

Section: Discussionmentioning

confidence: 99%

Oxidative Stress and Emergence of Psychosis

2022

View full text Add to dashboard Cite

Treatment and prevention strategies for schizophrenia require knowledge about the mechanisms involved in the psychotic transition. Increasing evidence suggests a redox imbalance in schizophrenia patients. This narrative review presents an overview of the scientific literature regarding blood oxidative stress markers’ evolution in the early stages of psychosis and chronic patients. Studies investigating peripheral levels of oxidative stress in schizophrenia patients, first episode of psychosis or UHR individuals were considered. A total of 76 peer-reviewed articles published from 1991 to 2022 on PubMed and EMBASE were included. Schizophrenia patients present with increased levels of oxidative damage to lipids in the blood, and decreased levels of non-enzymatic antioxidants. Genetic studies provide evidence for altered antioxidant functions in patients. Antioxidant blood levels are decreased before psychosis onset and blood levels of oxidative stress correlate with symptoms severity in patients. Finally, adjunct treatment of antipsychotics with the antioxidant N-acetyl cysteine appears to be effective in schizophrenia patients. Further studies are required to assess its efficacy as a prevention strategy. Redox imbalance might contribute to the pathophysiology of emerging psychosis and could serve as a therapeutic target for preventive or adjunctive therapies, as well as biomarkers of disease progression.

show abstract

“… 21 , 37 Both preclinical and clinical studies have suggested that long-term use of antipsychotics may promote neurotoxic free radical production, particularly for FGAs. 37 – 42 A recent meta-analysis indicated that patients with schizophrenia who received antipsychotics had higher levels of oxidative stress markers such as malondialdehyde and thiobarbituric acid reactive substances, as well as higher total oxidant status, compared with unmedicated patients. 42 Furthermore, animal studies have shown that long-term use of antipsychotics may increase the concentration of transition metals (e.g.…”

Section: Pathophysiology Of Tardive Dyskinesiamentioning

confidence: 99%

“…37–42 A recent meta-analysis indicated that patients with schizophrenia who received antipsychotics had higher levels of oxidative stress markers such as malondialdehyde and thiobarbituric acid reactive substances, as well as higher total oxidant status, compared with unmedicated patients. 42 Furthermore, animal studies have shown that long-term use of antipsychotics may increase the concentration of transition metals (e.g. iron, manganese and copper) in the striatum, which may also contribute to oxidative damage.…”

Section: Pathophysiology Of Tardive Dyskinesiamentioning

confidence: 99%

Pathophysiology, prognosis and treatment of tardive dyskinesia

Takeuchi

Mori

Tsutsumi

2022

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Tardive dyskinesia (TD), a movement disorder associated with antipsychotics, most frequently affects the lower face and jaw muscles, but can also affect walking, breathing and use of the hands and limbs. Knowledge of TD among physicians may be limited, and the pathophysiology of TD is poorly understood. We conducted this review to summarise the current knowledge surrounding the pathophysiology of TD and present recommendations for prevention and treatment based on a literature search and roundtable discussion attended by psychiatrists in Japan. It has been suggested that dopamine hypersensitivity, damaged gamma-aminobutyric acidergic neurons and/or increased production of reactive oxygen species may contribute to development of TD. Symptoms can profoundly affect everyday life; patients who develop TD have poorer prognoses, worse health-related quality of life, greater social withdrawal and higher mortality than patients without TD. Traditional treatment options include dietary supplements, although evidence for their effectiveness is low. Among pharmaceutical interventions, there is moderate evidence that switching to the second-generation antipsychotic clozapine, which has a lower affinity for dopamine D2 receptors than other antipsychotics, may improve symptoms. Vesicular monoamine transporter 2 (VMAT-2) inhibitors, which oppose the increased dopaminergic activity associated with prolonged antipsychotic use by interfering with dopamine uptake and storage, have the strongest evidence for efficacy. VMAT-2 inhibitors are approved in the United States for the treatment of TD, and the first VMAT-2 inhibitor was approved in Japan for this indication in March 2022. Most guidelines recommend treating TD by first reducing the dose of antipsychotics or switching to clozapine or other second-generation antipsychotics, which have a lower association with TD than first-generation antipsychotics. We recommend focusing on prevention and monitoring for TD when prescribing antipsychotics, given that TD is often irreversible. Physicians should treat with antipsychotics only when necessary and at the lowest effective dose, and frequently monitor for TD symptoms. Plain Language Summary Plain Language Summary (In Japanese) Visual Summary Visual Summary (In Japanese)

show abstract

Blood-based oxidation markers in medicated and unmedicated schizophrenia patients: A meta-analysis

Cited by 12 publications

References 105 publications

Oxidative Stress Biomarkers among Schizophrenia Inpatients

Oxidative Stress Biomarkers among Schizophrenia Inpatients

Oxidative Stress and Emergence of Psychosis

Pathophysiology, prognosis and treatment of tardive dyskinesia

Contact Info

Product

Resources

About